We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
114 hedge funds and large institutions have $85.6M invested in Lineage Cell Therapeutics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
5,700% more call options, than puts
Call options by funds: $58K | Put options by funds: $1K
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
1% more funds holding
Funds holding: 113 → 114 (+1)
0.07% more ownership
Funds ownership: 50.01% → 50.08% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less capital invested
Capital invested by funds: $94.2M → $85.6M (-$8.57M)
Holders
114
Holders Change
+1
Holders Change %
+0.88%
% of All Funds
1.64%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
8
Increased
30
Reduced
24
Closed
7
Calls
$58K
Puts
$1K
Net Calls
+$57K
Net Calls Change
-$43K
Top Buyers
| 1 |
BlackRock
New York
|
+$334K |
| 2 |
Morgan Stanley
New York
|
+$298K |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$278K |
| 4 |
Barclays
London,
United Kingdom
|
+$148K |
| 5 |
RA
Raffles Associates
New York
|
+$139K |
Top Sellers
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$580K |
| 2 |
Renaissance Technologies
New York
|
-$358K |
| 3 |
PGP
Prescott General Partners
Boca Raton,
Florida
|
-$217K |
| 4 |
Millennium Management
New York
|
-$169K |
| 5 |
Jane Street
New York
|
-$114K |
